Colonic EBV-Associated Lymphoproliferative Disorder in a Patient Treated with Rabbit Antithymocyte Globulin for Aplastic Anemia

Table 1

Summary of EBV-LPD after ATG for aplastic anemia in a nontransplant setting.

Age, gender	Type of ATG	Dose of ATG	Other drugs	Months to diagnosis from ATG	EBV viral load	Type of LPD	Previous treatment for AA	Treatment for LPD	Outcome	Reference
38, M	Equine	3.5 mg/kg NR	mPSL, CSP	1>	30,000/150,000 cells	IM	rATG	Rit	CR	[7]
36, M	Equine	0.75 mL/kg 8 days	CSP	1>	NR	EBV-LPD	NR	NR	Dead	[8]
55, M	Equine	NR	None	1	60,060/mL	EBV-LPD	ATG*	GCV**, FCV** Rit	NR	[9]
42, F	Rabbit	12.5 mg/kg 4 days	CSP	1>	4 × 10^6/mL	DLBCL	eATG	Rit, CPA	CR	[10]
55, M	Rabbit	3.75 mg/kg 5 days	mPSL, CSP	3	140/10^6 WBC	EBV-LPD	None	Cessation of CSP	CR	Our case

NR: not reported, IM: infectious monocytosis, rATG: rabbit ATG, eATG: equine ATG, Rit: rituximab, CR: complete remission, EBV-LPD: Epstein-Barr-virus-associated lymphoproliferative disorder, GCV: ganciclovir, FCV: foscarnet, DLBCL: diffuse large B-cell lymphoma, CPA: cyclophosphamide, and CSP: cyclosporine.
*This patient received autologous peripheral blood stem cell transplantation for Burkitt lymphoma before development of aplastic anemia.
**For concurrence of cytomegalovirus reactivation.